RGEN Repligen Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: RGEN

Price (delayed)

$157.06

Market cap

$8.76B

P/E Ratio

209.41

Dividend/share

N/A

EPS

$0.75

Enterprise value

$8.72B

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in ...

Highlights
RGEN's quick ratio has surged by 173% since the previous quarter
Repligen's equity has increased by 3.2% YoY
The stock's P/E is 95% above its last 4 quarters average of 107.2 and 63% above its 5-year quarterly average of 128.1
The company's net income has shrunk by 78% YoY and by 64% QoQ
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: https://www.repligen.com/
Peers: NVAX NBIX BMRN PFE

Key stats

What are the main financial stats of RGEN
Market
Shares outstanding
55.77M
Market cap
$8.76B
Enterprise value
$8.72B
Valuations
Price to earnings (P/E)
209.41
Price to book (P/B)
4.45
Price to sales (P/S)
13.7
EV/EBIT
131.95
EV/EBITDA
64.99
EV/Sales
13.65
Earnings
Revenue
$638.76M
EBIT
$66.08M
EBITDA
$134.17M
Free cash flow
$74.93M
Per share
EPS
$0.75
Free cash flow per share
$1.34
Book value per share
$35.31
Revenue per share
$11.46
TBVPS
$25.79
Balance sheet
Total assets
$2.82B
Total liabilities
$853.21M
Debt
$711.8M
Equity
$1.97B
Working capital
$952.88M
Liquidity
Debt to equity
0.36
Current ratio
7.02
Quick ratio
5.54
Net debt/EBITDA
-0.29
Margins
EBITDA margin
21%
Gross margin
44.6%
Net margin
6.5%
Operating margin
8.5%
Efficiency
Return on assets
1.6%
Return on equity
2.1%
Return on invested capital
7.4%
Return on capital employed
2.5%
Return on sales
10.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGEN stock price

How has the Repligen stock price performed over time
Intraday
-2.44%
1 week
-10.8%
1 month
-19.15%
1 year
-7.67%
YTD
-12.65%
QTD
-14.6%

Financial performance

How have Repligen's revenue and profit performed over time
Revenue
$638.76M
Gross profit
$284.84M
Operating income
$54.58M
Net income
$41.58M
Gross margin
44.6%
Net margin
6.5%
The company's net income has shrunk by 78% YoY and by 64% QoQ
The operating income has plunged by 76% YoY and by 48% from the previous quarter
The net margin has plunged by 72% YoY and by 62% from the previous quarter
The operating margin has plunged by 70% YoY and by 46% from the previous quarter

Growth

What is Repligen's growth rate over time

Valuation

What is Repligen stock price valuation
RGEN P/E details
P/E
209.41
P/B
4.45
P/S
13.7
EV/EBIT
131.95
EV/EBITDA
64.99
EV/Sales
13.65
The stock's P/E is 95% above its last 4 quarters average of 107.2 and 63% above its 5-year quarterly average of 128.1
RGEN's EPS has dropped by 78% year-on-year and by 64% since the previous quarter
The P/B is 22% less than the 5-year quarterly average of 5.7 and 3.3% less than the last 4 quarters average of 4.6
Repligen's equity has increased by 3.2% YoY
RGEN's P/S is 23% below its 5-year quarterly average of 17.7 but 6% above its last 4 quarters average of 12.9
The revenue has contracted by 20% YoY and by 4.6% from the previous quarter

Efficiency

How efficient is Repligen business performance
The return on equity has dropped by 79% year-on-year and by 64% since the previous quarter
RGEN's ROA has dropped by 79% year-on-year and by 65% since the previous quarter
The ROIC has plunged by 77% YoY and by 54% from the previous quarter
RGEN's return on sales has dropped by 63% year-on-year and by 46% since the previous quarter

Dividends

What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGEN.

Financial health

How did Repligen financials performed over time
Repligen's current ratio has surged by 184% YoY and by 161% QoQ
RGEN's quick ratio has surged by 173% since the previous quarter
The debt is 64% less than the equity
Repligen's debt to equity has soared by 71% from the previous quarter and by 64% YoY
The debt has soared by 70% from the previous quarter and by 68% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.